Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProteoNic and OET Sign UNic™ License for Use in flashBAC™

Published: Friday, March 08, 2013
Last Updated: Friday, March 08, 2013
Bookmark and Share
Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13.

ProteoNic BV and Oxford Expression Technologies Ltd (OET) have extended their partnership by signing a commercial license agreement.

OET obtains the right to use ProteoNic’s UNic™ translation enhancing elements in its flashBAC™ system for third party recombinant protein production services.

ProteoNic will provide technical support. Financial terms include upfront and royalty payments.

Both companies will be represented at BIO Europe Spring in Barcelona on March 11 -13 and are available for partnering meetings.

Under a previous collaboration, the two companies have successfully combined ProteoNic’s award-winning UNic™ translation enhancing technology with OET’s flashBAC™ system to significantly enhance recombinant protein yields in insect cells.

Application of UNic™ not only allows increased overall efficiency and reduction of costs, but also facilitates (pre)clinical development of biopharmaceutical products that otherwise might be discarded due to difficulties in achieving acceptable production levels.

This allows biopharmaceutical companies to broaden their pipeline and increase its value while reducing the drug development risk profile. From now on OET’s contract manufacturing services will include UNic™ technology.

Rory Woodhouse, Sales Manager at OET commented: “The combination of the unique UNic™ technology and the flashBAC™ expression system has already proved itself to have a positive effect on eukaryotic protein expression. This new agreement will enable us to build on our partnership and experience with ProteoNic, working together to provide a superior platform for our customers with more challenging to express proteins.”

Victor Schut, Chief Business Officer at ProteoNic added: “We are pleased to have demonstrated the value of partnership in combining two proven technologies. This will allow our customers to benefit from both our expertise through only one service. The successful application of our technology in the flashBAC system adds another recombinant protein production platform to our portfolio enabling us to serve a new market for ProteoNic.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProteoNic Announces Closing of Financing Round
Completion of a € 6 mln equity financing round led by US-based Fairbanks Investment Fund.
Monday, October 03, 2011
ProteoNic and OET Join Forces Combining UNic™ with flashBAC™ Protein Expression Platform
Companies combine ProteoNic’s award winning UNic™ translation enhancement technology with OET’s flashBAC™ system to enhance protein yields.
Thursday, March 10, 2011
Scientific News
Open Source Seed Initiative – A Welcome Boost to Global Crop Breeding
A team of plant breeders, farmers, non-profit agencies, seed advocates, and policymakers have created the Open Source Seed Initiative.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
A New Way Out for Stem Cells
Researchers at North Carolina State University have discovered that therapeutic stem cells exit the bloodstream in a different manner than was previously thought.
One Giant Leap for the Future of Safe Drug Delivery
Sheffield engineers make major breakthrough in developing silk ‘micro-rockets’ that can be used safely in biological environments.
Designing Potential AIDS Vaccine Candidates
Findings represent ‘big accomplishment’ in biomedical engineering and design.
Anticancer Drug Stops Ebola Virus Molecule in its Tracks
A team of scientists from the University of Oxford have successfully mapped the structure of the Ebola virus molecule that drives the attack strategy and leads to fatal infections in humans.
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
Anthrax Proteins Might Help Treat Cancerous Tumors
Studies in mice reveal novel treatment regimen.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Key to Chronic Fatigue Syndrome is in Your Gut, Not Head
Researchers report they have identified biological markers of the disease in gut bacteria and inflammatory microbial agents in the blood.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!